Managing Pasireotide-Induced Hyperglycemia in Cushing’s Disease and Acromegaly
Author Information
Author(s): Witek Przemysław, Bolanowski Marek, Krętowski Adam, Głowińska Aleksandra
Hypothesis
The study aims to review and propose algorithms for managing pasireotide-induced hyperglycemia in patients with Cushing’s disease and acromegaly.
Conclusion
Pasireotide can effectively treat Cushing’s disease and acromegaly, but it may cause hyperglycemia, which can often be managed with diet and oral antidiabetic agents.
Supporting Evidence
- Pasireotide is effective in treating Cushing’s disease and acromegaly.
- About 25% of patients with Cushing’s disease and 50% with acromegaly can manage hyperglycemia without drug therapy.
- Metformin is suggested as the first-line therapy for managing pasireotide-induced hyperglycemia.
Takeaway
Pasireotide helps treat certain diseases but can make blood sugar levels go up, which can usually be managed with diet and medicine.
Methodology
The study reviews previous recommendations and proposes monitoring and treatment algorithms based on recent evidence and guidelines.
Limitations
The study's conclusions are based on limited data from small patient populations with rare diseases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website